Navigation Links
Mayo researchers: complementary therapies help patients recover after heart surgery
Date:10/31/2007

of the need for surgery, so they can use them prior to surgery, she says.

  • Stress education classes: The team partnered with the Mayo Clinic Patient Education Center to offer pilot stress management skill classes to inpatients and their family members. The classes work well because patients often are in the hospital for several days following surgery, Cutshall says. Classes are conducted twice a week on the cardiac surgery units.

"These services are outside the realm of what surgeons are typically taught in medical school; we tend to always want to see the evidence," says Thoralf Sundt, M.D., co-author and a cardiovascular surgeon at Mayo Clinic. "But we quickly could see the benefits to patients and that's the bottom line for us. We see this as looking out for all the needs of our patients."


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related medicine news :

1. UC Researchers: Low-cost malaria cure will not be a distant dream
2. Complementary and Alternative medicine
3. Complementary Therapy may Reduce Pregnancy Chances in Women
4. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
5. Alternative therapies popular with Parkinsons patients
6. Prolonged survival not assured by psychological therapies for cancer patients
7. First head-to-head trials of once weekly Fosamax and Actonel therapies
8. Preventive Therapies Found to be More Effective in Managing Migraines
9. Ayurvedic Therapies Cashing In On Medical Tourism
10. Immune-Boosting Therapies Of No Use In Preventing Miscarriage
11. A urine test for ease in prescription of drugs and therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... scientists have found the first potential immunological clue of ... the pandemic H1N1 virus. , The study analyzed ... 15 outpatients and 15 control subjects in 10 Spanish ... August 2009. Researchers from the Hospital Clinico Universitario de ... high levels of a molecule called interleukin 17 in ...
(Date:12/15/2009)... ATLANTA, GADecember 15, 2009Do good-looking people really benefit from ... researchers from the University of Georgia and the University ... to have more social relationships and therefore an increased ... and might be why we spend billions of dollars ... study, published in this month,s issue of Personal ...
(Date:12/15/2009)... Leading Workers, Compensation Carrier Confirms PMSI as Solution Provider ... ... Tampa, FL (Vocus) December 15, 2009 -- PMSI, ... providers of specialty products and services for the workers’ ... (KEMI) has decided to renew its pharmacy services (retail ...
(Date:12/15/2009)... deemed safer than wood fiber , , TUESDAY, Dec. 15 (HealthDay ... arm in a fall are much lower on playgrounds with ... new research has found. , Researchers at the Hospital for ... playground surfaces of either granite sand or engineered wood fiber. ... Medicine . , The risk of a broken arm resulting ...
(Date:12/15/2009)... study finds , , TUESDAY, Dec. 15 (HealthDay News) -- Tight ... with type 2 diabetes who have other medical problems, a ... in type 2 diabetes "has been a subject of controversy ... medicine at the University of California at Irvine, and lead ... the Annals of Internal Medicine . "Our work attempts ...
Breaking Medicine News(10 mins):Health News:First immunological clue to why some H1N1 patients get very ill or die 2Health News:The importance of attractiveness depends on where you live 2Health News:KEMI Renews Contract With PMSI 2Health News:Tighter Blood Sugar Control Not Best for Some Diabetics 2Health News:Tighter Blood Sugar Control Not Best for Some Diabetics 3
... EntreMed, Inc.,(Nasdaq: ENMD ) a clinical-stage ... and inflammatory diseases,announced today that James S. Burns, ... overview at the Acumen BioFin Rodman & Renshaw ... New York Palace Hotel in,New York, November 5-7, ...
... BPUR ) announced today that the trading symbol ... to BPUR at the open of the market on,Wednesday, ... OTCBB,will revert to the following ticker symbols: BPREW reverting ... BPURL. Biopure Corporation Biopure Corporation develops, manufactures ...
... FRANCISCO, Calif., Oct. 31 Anesiva,Inc. (Nasdaq: ANSV ... chief executive officer, will present at the following events ... November 6, 2007 3:45 p.m. ET ... Healthcare Conference November 27, 2007 4:30 p.m. ...
... QUEBEC CITY, Oct. 31 /PRNewswire-FirstCall/ - AEterna Zentaris ... focused on,endocrine therapy and oncology, will announce its ... open on Wednesday, November,7, 2007. The Company will ... results on the same day at 10:00 a.m. ...
... NORTHAMPTON, Mass., Oct. 31 Physicians ... posts to Healthcommunities.com,Inc.,s healthchannels forum,( http://www.healthcommunities.com/health/forums.shtml ... physician post was submitted to the ... hosted and maintained by,Healthcommunities.com, Inc. (HC), ...
... ALTH ), a biopharmaceutical company focused on,the development ... cancer, today announced that Paul L. Berns, President and,CEO, ... BioFin Rodman &,Renshaw Conference in New York. The ... on,Tuesday, November 6, 2007. There will be a live ...
Other Medicine News:Health News:EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference 2Health News:Biopure's Stock Symbol Reverts to BPUR 2Health News:Anesiva Announces Upcoming Webcasts and Conference Participation 2Health News:Free Site Offering Patient-Physician Dialog Reaches Milestone 2Health News:Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference 2
(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com announces ... available in its catalogue: ,, Boehringer ... http://www.reportlinker.com/p0168539/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile.html ,, Introduction ,, ... performance for Boehringer Ingelheim in the Rx ... portfolio and pipeline analysis and assessment of ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The Future ... to 2015, Competitive Benchmarking, Product Pipeline ... http://www.reportlinker.com/p0168102/The-Future-of-HIV-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, Summary ... latest research "The Future of HIV ...
(Date:12/15/2009)... Belgium, Dec. 15 Ghent University Hospital ... world to pioneer radiotherapy treatments using arc therapy, ... and efficient RapidArc radiotherapy technology from Varian Medical ... patient was treated in just 75 seconds, over ... treatments. ,, "This treatment would have taken more ...
Breaking Medicine Technology:Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient 2European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient 3New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 1New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 2New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 3Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 1Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 2Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 3Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 1Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 2Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 3Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 5
... Nov. 24 A new cancer treatment is,realizing ... treatment, a patient,s large, stage 4 tumor was ... of treatment, it no longer could be definitely,identified ... to nine months,after diagnosis. NeoPlas Innovation,s combination of ...
... moderate to severe acute pain and their health-care providers will ... Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD), announced that the ... for the relief of moderate to severe acute pain in ... , Tapentadol is a new centrally acting ...
Other Medicine Technology:New Cancer Treatment Shrinks Pancreatic Tumor 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 3FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 4FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 6
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: